Cell News and Research

RSS

Studies examine interaction of ribosome with molecular partners

Two new studies reveal in unprecedented detail how the ribosome interacts with other molecules to assemble new proteins and guide them toward their destination in biological cells. The studies used molecular dynamics flexible fitting (MDFF) to examine the interaction of the ribosome with two prominent molecular partners.

24 Nov 2009

SANYO releases whitepaper on its new cell culture CO2 incubator

SANYO North America's Biomedical and Environmental Division has released a new whitepaper showing that higher up-time ratios, based on new protocols that minimize incubator downtime when compared to conventional decontamination methods, can accelerate a return on investment in cell culture CO2 incubators that use hydrogen peroxide vapor (H2O2) in conjunction with narrow-bandwidth ultraviolet light and copper-enriched stainless steel.

24 Nov 2009

Andor Technology reports 2009 preliminary results

ANDOR TECHNOLOGY PLC ("Andor") Preliminary Results for the year ended 30 September 2009 24 November 2009 Andor Technology plc (AND.L), the leading developer and manufacturer of high performance digital cameras and solutions for academic, industrial and government applications globally, today announces preliminary results for the year ended 30 September 2009.

24 Nov 2009

Scientists determine how insulin resistant drugs alter core biochemical pathways through systems biology approach

Researchers from the University of California, San Diego recently offered the sharpest-yet picture of how core biochemical pathways in skeletal muscle cells and fat cells are altered in people who suffer from insulin resistance-a primary defect in type 2 diabetes and obesity. Taking a systems biology approach, the bioengineers and medical researchers also determined how a common class of drugs for treating insulin resistance-TZDs-alter these same core pathways.

24 Nov 2009

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Clavis Pharma ASA, the clinical stage oncology focused pharmaceutical company, and Clovis Oncology, Inc., the newly formed oncology company led by former Pharmion Corporation executives, announced today an agreement for the further development and commercialisation of the Clavis Pharma drug candidate, CP-4126, currently in Phase II development in pancreatic cancer.

24 Nov 2009

Seattle Genetics and Agensys expand ADC collaboration

Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Inc., an affiliate of Astellas, announced today an expansion of the companies’ antibody-drug conjugate (ADC) collaboration. Under the amended agreement, Agensys will pay a $12 million fee for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at the time of investigational new drug (IND) submission.

24 Nov 2009

NIGMS invests $42.3 million in "Grand Opportunities" grant

The National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH), is investing $42.3 million for grants in scientific areas it identified as "Grand Opportunities (GO)." NIH developed the GO grant program to stimulate biomedical research and the economy using funds provided by the American Recovery and Reinvestment Act (Recovery Act).

24 Nov 2009

PX’Therapeutics sets up additional biomanufacturing unit

PX’Therapeutics SA (formerly known as Protein’eXpert) announces the set up of an additional biomanufacturing unit dedicated to the production of therapeutic proteins and monoclonal antibodies in mammalian cells.

24 Nov 2009

Human-derived UCB stem cell transplant has positive therapeutic effects on specific lung and heart disorders

Two separate studies published in the current issue of Cell Transplantation (18:8), - now freely available on-line at http://www.ingentaconnect.com/content/cog/ct - have shown that transplanted human-derived umbilical cord blood (UCB) stem cells transplanted in an animal model had positive therapeutic effects on specific lung and heart disorders the animal models.

24 Nov 2009

New initiative launched to take care of patients with sickle cell disease

The Medical College of Georgia is leading an initiative that could result in a paradigm shift in the care of patients with sickle cell disease.

23 Nov 2009

Mutated IDH1 gene linked to the progression of gliomas

23 Nov 2009

C3a peptide regulates the generation of new nerve cells in the brain: Study

The generation of new nerve cells in the brain is regulated by a peptide known as C3a, which directly affects the stem cells' maturation into nerve cells and is also important for the migration of new nerve cells through the brain tissue, reveals new research from the Sahlgrenska Academy published in the journal Stem Cells.

23 Nov 2009

Lobbying is up as health industry examines impact of reform proposals

"Companies and groups hiring lobbying firms on health issues nearly doubled this year as special interests rushed to shape the massive revamp of the nation's health care system now in its final stretch before Congress." As many as 1,000 groups "have hired lobbyists since January, compared with 505 during the same period in 2008, according to a USA TODAY analysis of congressional records compiled by the nonpartisan CQ MoneyLine."

23 Nov 2009

Horizon Health International, Exmovere Holdings enter into a marketing and distribution agreement

HORIZON HEALTH INTERNATIONAL CORP. is pleased to announce that it has executed a Definitive Agreement with Exmovere Holdings Inc. of McLean, Virginia USA (Exmovere). Under the terms of the Agreement Horizon will pay Exmovere a total of two million dollars over a one year period for the exclusive rights to market and distribute their products in Canada for a 15 year term.

23 Nov 2009

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.

23 Nov 2009

Asterand extends its collaboration agreement with Bristol-Myers Squibb

Asterand plc, a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years.

23 Nov 2009

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, today announced positive interim results from a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) plinabulin (NPI-2358) in combination with standard chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC).

23 Nov 2009

Phase IIb/III clinical trial results of CINQUIL for pediatric EoE announced

Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms.

23 Nov 2009

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

ARIAD Pharmaceuticals, Inc. today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical trial of ARIAD’s investigational, multi-targeted kinase inhibitor and pan-BCR-ABL inhibitor, AP24534, at the 51st Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, Louisiana, December 5-8, 2009.

23 Nov 2009

100th patient enrolled in Atrium Medical's iCAST Atrium Registry Ultrasound Study

Atrium Medical Corporation announced that the 100th patient was enrolled in the iCAST™ Atrium Registry Ultrasound Study (iCARUS). The iCARUS study is a prospective, multi-center clinical trial studying the safety and efficacy of the Atrium iCAST™ Balloon Expandable Covered Stent in patients with occlusive disease in the iliac artery.

23 Nov 2009

Cell News and Research

Studies examine interaction of ribosome with molecular partners

SANYO releases whitepaper on its new cell culture CO2 incubator

Andor Technology reports 2009 preliminary results

Scientists determine how insulin resistant drugs alter core biochemical pathways through systems biology approach

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Seattle Genetics and Agensys expand ADC collaboration

NIGMS invests $42.3 million in "Grand Opportunities" grant

PX’Therapeutics sets up additional biomanufacturing unit

Human-derived UCB stem cell transplant has positive therapeutic effects on specific lung and heart disorders

New initiative launched to take care of patients with sickle cell disease

Mutated IDH1 gene linked to the progression of gliomas

C3a peptide regulates the generation of new nerve cells in the brain: Study

Lobbying is up as health industry examines impact of reform proposals

Horizon Health International, Exmovere Holdings enter into a marketing and distribution agreement

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Asterand extends its collaboration agreement with Bristol-Myers Squibb

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Phase IIb/III clinical trial results of CINQUIL for pediatric EoE announced

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

100th patient enrolled in Atrium Medical's iCAST Atrium Registry Ultrasound Study

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News